association

Full identifier: http://purl.org/np/RAWRimmQ-xstIebo9KN6P9BXNESYJ0iLxkMi9osXoFWE8#association

Assigned to 1 class:

Minted in Nanopublication

 RAWRimmQ-x comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAWRimmQ-x...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAWRimmQ-x... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T15:02:05.198+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAWRimmQ-x... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAWRimmQ-x... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAWRimmQ-x... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:02:05.198Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 1 1 active psoriatic arthritis psa alone or in combination with methotrexate 1 2 active ankylosing spondylitis as 1 3 moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 1 4 inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders simponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis simponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritis simponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6 mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 14 4
Leoni Bücken
2021-07-03T13:02:05.198Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:02:05.198Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:02:05.198Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:02:05.198Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:02:05.198Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:02:05.198Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T13:02:05.198Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)